Neurocrine New Drug Applications, Priority Review for congenital adrenal hyperplasia

 

• PDUFA Target Action Dates in Late December 2024
• Highly Selective CRF₁ Antagonist is the Potential First New Treatment for CAH in 70 Years

https://www.biospace.com/article/releases/neurocrine-biosciences-announces-u-s-fda-accepts-new-drug-applications-and-grants-priority-review-for-crinecerfont-for-pediatric-and-adult-patients-with-cah/